• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

    7/16/24 9:00:00 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email

    AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in Alberta.

    EDMONTON, AB, July 16, 2024 /CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early stage Alberta health and life science startups the continuing opportunity to access Amplitude's specialized precision medicine expertise and investment. Amplitude is also establishing a full-time presence in Alberta with a new hire.

    Alberta Enterprise Corporation promotes the development of Alberta's venture capital industry by investing in venture capital funds that finance technology companies. We focus on funds that have a strong commitment to Alberta – including a full-time presence in the province. In addition to financial capital, we support Alberta's venture capital ecosystem by connecting investors, entrepreneurs, and experienced technology executives who share our passion for building a bright, innovative Alberta. (CNW Group/Alberta Enterprise Corporation)

    Amplitude Ventures is a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI. Since 2019, the firm has invested in entrepreneurs creating and building precision health companies including Repare Therapeutics (NASDAQ:RPTX), Abdera, Valence (acquired by Recursion) and Edmonton's DrugBank which has developed the world's most comprehensive drug knowledge platform. AEC invested in Amplitude's first fund and is returning as an investor in Fund II.

    "Alberta life science startups require access to capital and expertise from specialized life science investors in order to scale," commented Kristina Williams, CEO, Alberta Enterprise Corporation. "Amplitude contributes deep expertise to help Alberta entrepreneurs building new precision medicine companies which can drive meaningful outcomes in human health and transform the future of healthcare."

    Amplitude is led by partners Dion Madsen, Jean-Francois Pariseau, Ali Tehrani and venture partner, Nancy Harrison. Madsen began his venture career in Edmonton and sat on the board of BioAlberta. He expanded his career in San Francisco, a key life sciences hub, before helping start Amplitude in 2018. Amplitude built an early connection to Alberta in 2022 via a strategic alliance with Edmonton-based AltaML bringing together the AI and ML expertise of AltaML and the life science company building expertise of Amplitude. With the final close of Fund II, Amplitude is announcing the hire of a full-time investor, Nadia Lachman, based in Calgary. Lachman, a University of Calgary alum, brings a background in health science and biomedical technology and well as venture capital investment experience.

    "Witnessing Alberta's emerging strength in AI and its application to Precision Medicine, we see an opportunity here to support entrepreneurs with major growth aspirations," said Dion Madsen, Partner at Amplitude Ventures.  "We're thrilled to continue our partnership with AEC and deepen our connections in Alberta, so we can offer local startups access to the team, the growth model and the investment strategy that has made us the leading life sciences fund to work within Canada."

    "Thanks to Alberta's strong universities and machine learning community, local teams are combining knowledge in AI and biotech to build promising health startups here," said Nate Glubish, Minister of Technology and Innovation. "This latest investment by AEC helps ensure that more great research projects coming out of our post-secondary institutions can commercialize and grow into successful companies."

    About Alberta Enterprise Corporation: alberta-enterprise.ca

    Alberta Enterprise Corporation (AEC) promotes the development of Alberta's venture capital industry by investing in venture capital funds that finance technology companies. AEC focuses on funds that have a strong commitment to Alberta – including a full-time presence in the province. In addition to financial capital, AEC supports Alberta's venture capital ecosystem by connecting investors, entrepreneurs, and experienced technology executives who share our passion for building a bright, innovative Alberta. As of March 31, 2024, AEC has committed C$367 million for investment to thirty-five venture capital funds, covering a diverse range of forward-looking industries including information technology, energy and industrial technology, and life sciences.

    About Amplitude: amplitudevc.com

    Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build companies with world-class management teams and to scale companies to breakout potential. With more than $500 million in assets under management and offices in Montreal, Toronto, Calgary and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies.

    SOURCE Alberta Enterprise Corporation

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/16/c3448.html

    Get the next $RPTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    SEC Filings

    View All

    SEC Form EFFECT filed by Repare Therapeutics Inc.

    EFFECT - Repare Therapeutics Inc. (0001808158) (Filer)

    2/2/26 12:15:08 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.

    SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)

    1/30/26 6:39:53 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Repare Therapeutics Inc.

    S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)

    1/28/26 5:13:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Bvf Partners L P/Il

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    1/30/26 6:44:11 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rhoads Ann D returned 4,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    1/28/26 8:30:10 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schafer Carol returned 8,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    1/28/26 8:30:12 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    11/17/23 4:54:43 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

    4 - Repare Therapeutics Inc. (0001808158) (Issuer)

    11/3/23 5:37:44 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of the Common Shares, the "Shareholders") by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno") a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.76% of the votes cast b

    1/16/26 4:58:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the "Gilead Agreement"). "We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor," said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. "This marks the third and most significant portfolio transaction for Repare this year." Under the terms of the Gilead Agreemen

    12/24/25 7:00:00 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, "Xeno"), a non-profit biotechnology company, pursuant to which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of Repare (the "Common Shares"), certain entities affiliated with BVF Partners L.P., Blue Owl Healthcare Opportunities, and certain entities affiliated with OrbiMed have each entered into a support and voting agreement pursuant to which they ha

    11/20/25 5:25:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Repare Therapeutics upgraded by Stifel with a new price target

    Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

    6/9/23 7:34:45 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

    2/3/23 7:35:18 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on Repare Therapeutics with a new price target

    CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

    1/6/23 8:30:21 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Leadership Updates

    Live Leadership Updates

    View All

    Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of the Common Shares, the "Shareholders") by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno") a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.76% of the votes cast b

    1/16/26 4:58:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

    Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

    5/7/24 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 9:00:57 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 5:05:19 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

    SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

    11/14/24 9:42:55 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPTX
    Financials

    Live finance-specific insights

    View All

    Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

    Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

    5/1/25 7:00:00 AM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

    Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

    12/12/24 4:20:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

    Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

    12/10/24 4:05:00 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care